Core Insights - Addex Therapeutics has entered into an option- and collaboration agreement with Sinntaxis AB for an exclusive license to intellectual property related to mGlu5 inhibitors aimed at brain injury recovery [1][2] - The collaboration will focus on the preclinical validation of Addex's lead drug candidate, dipraglurant, which is an mGlu5 negative allosteric modulator [2][3] - The mGlu5 receptor is believed to play a significant role in brain plasticity and functional recovery following brain injuries such as strokes [4] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in novel small molecule allosteric modulators for neurological disorders [5] - The company's lead candidate, dipraglurant, is being evaluated for its potential in treating brain injury recovery, including post-stroke and traumatic brain injury [5] - Addex also has partnerships and programs targeting other neurological conditions, including a GABAB PAM program for chronic cough and a 20% equity interest in Neurosterix LLC [5]